Supported by Grants from the National Key Basic Research Program of China, No. 2009CB522507, No. 2012CB519005;Beijing Nova Program of China, No. Z12110702512071
Combination therapy with peginterferon (pegIFN)-α and ribavirin (RBV) has been the standard of care (SOC) for chronic hepatitis C. Unfortunately, not all patients can achieve a sustained virologic response (SVR) with...